0
61
Psychiatric News   |   March 19, 2004 
Volume 39 Number 6 page 70-70
Clinical and Research News
  • Print
  • E-mail
    Recipient(s) will receive an email with a link (good for 72 hours) to 'Psychosis Has Minimal Impact on Neurocognition' and do not need to have Psychiatric News account to access the content.
    Example: John Doe
    CC Me:
    Enter your valid email address. Example: jdoe@example.com
    Separate multiple email address with semi-colons (up to 5).
    's Psychiatric News: 'Psychosis Has Minimal Impact on Neurocognition'
    Subject for your email.
    (Optional, message will truncate at 1000 characters)
    Copyright © in the material you requested is held by The American Psychiatric Association (unless otherwise noted). This email ability is provided as a courtesy, and by using it you agree that you are requesting the material solely for personal, non-commercial use, and that it is subject to The American Psychiatric Association's Terms of Use. The information provided in order to email this topic will not be used to send unsolicited email, nor will it be furnished to third parties. Please refer to The American Psychiatric Association's Privacy Policy for further information.
    Copyright © American Psychiatric Association. All rights reserved.
  • Share
  • Reprints
Psychosis Has Minimal Impact on Neurocognition
text A A A
View Disclosures and Other Information
Delaying treatment for psychosis doesn’t seem to have negative effects on a person’s ability to learn, remember, and otherwise engage in neuropsychological processes.
From a common-sense perspective, one would expect psychosis to wreck havoc with a person’s efforts to learn, remember, react, and otherwise use his or her brain. One might also expect that putting off treatment for psychosis would have a baleful effect on neurocognition as well.
Intuition, however, may not always be right, a new study reported in the March American Journal of Psychiatry suggests. It has found no adverse neurocognitive effects either from psychosis or from delaying treatment for it.
The study was conducted by Björn Rund, Ph.D., a psychologist at the University of Oslo in Norway, other Norwegian investigators, and Thomas McGlashan, M.D., a professor of psychiatry at Yale University.
The investigation included 207 Norwegian subjects who were diagnosed for the first time with schizophrenia, schizophreniform disorder, schizoaffective disorder, brief psychotic episode, delusional disorder, affective psychosis with mood incongruent delusions, or psychotic disorder not otherwise specified.
The subjects were assessed for symptoms three months after starting treatment. The subjects were also given neuropsychological tests after they were stabilized or experienced symptom remission, which was, on average, about three months after starting treatment. The neuropsychological tests evaluated verbal learning, working memory, motor speed, and executive function. They included, for example, the California Verbal Learning Test, the Finger-Tapping Test, and the Wisconsin Card-Sorting Test.
The researchers then attempted to see whether there were significant links between the subjects’ psychotic symptoms at three months after starting treatment and their neuropsychological test results at stabilization or remission, which was, on average, also three months after starting treatment.
They found neither, suggesting that psychosis had little impact on neurocognition. And even when the investigators looked only at subjects who were not experiencing remission from their psychotic symptoms at the time of neuropsychological testing, which was 43 percent of subjects, they still could find no strong connections between psychosis and neurocognition.
Thus psychosis appears to have minimal impact on neurocognition, they concluded.
The investigators then looked for a significant link between duration of untreated psychosis in the subjects—that is, the time from onset of psychotic symptoms to the start of adequate treatment for psychosis—and the subjects’ neuropsychological test scores at the time of stabilization or remission. They again failed to find a link, implying that putting off treatment for psychosis does not damage neurocognition.
A similar result has been obtained by other researchers—for instance, Beng-Choon Ho, M.D., clinical director of the University of Iowa Schizophrenia Research Center, and coworkers (Psychiatric News, January 7, 2003). Some other scientists, however, have found the opposite—for example, Delbert Robinson, M.D., a research psychiatrist with Zucker Hillside Hospital in Glen Oaks, N.Y., and colleagues (see page 64).
So why have some researchers found that delaying treatment for psychosis does not hurt neurocognition, whereas others have found the opposite? One possibility, Robinson told Psychiatric News, is that the biological underpinnings of persons with first-episode schizophrenia or schizoaffective disorder differ from the biological underpinnings of persons with other types of first-episode psychosis. As a result, delaying psychosis treatment might impair neurocognition in the former group, but not in the latter.
The study was funded by the Norwegian Research Council, the National Council for Mental Health/Health and Rehabilitation, the National Institute of Mental Health, the Norwegian Health Ministry, and the Theodore and Vada Stanley Foundation.
The study, "Neurocognitive Dsyfunction in First-Episode Psychosis: Correlates With Symptoms, Premorbid Adjustment, and Duration of Untreated Psychosis," is posted online at http://ajp.psychiatryonline.org/cgi/content/full/161/3/466. ▪
Am J Psychiatry  2004161466

Interactive Graphics

Video

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s “Cited By” API will populate this tab (http://www.crossref.org/citedby.html).
Compression-Only CPR: Pushing the Science Forward
Cone
AAM 2010;304:1493-1495.
All you need to read in the other general jounals
BMJ 2010;341:c5893-c1494.
Submit a Comments
Please read the other comments before you post yours. Contributors must reveal any conflict of interest.
Comments are moderated and will appear on the site at the discertion of JBJS editorial staff.

* = Required Field
(if multiple authors, separate names by comma)
Example: John Doe



Copyright ©
American
Psychiatric
Association